Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

<h4>Background</h4> <p>The EQUATOR trial investigated the efficacy and safety of filgotinib, a selective Janus kinase 1 (JAK1) inhibitor, for the treatment of psoriatic arthritis (PsA).</p> <h4>Methods</h4> <p>This completed, randomised, double-blind, place...

Full description

Bibliographic Details
Main Authors:	Mease, P, Coates, L, Helliwell, P, Stanislavchuk, M, Rychlewska-Hanczewska, A, Dudek, A, Abi-Saab, W, Tasset, C, Meuleners, L, Harrison, P, Besuyen, R, Van Der Aa, A, Mozaffarian, N, Greer, J, Kunder, R, Van Den Bosch, F, Gladman, D
Format:	Journal article
Published:	Elsevier 2018

Similar Items

Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)
by: Orbai, A-M, et al.
Published: (2019)

Filgotinib, an oral JAK1 selective inhibitor with a rapid onset of action: results from the DARWIN 1 study in methotrexate inadequate response rheumatoid arthritis patients
by: Taylor, P, et al.
Published: (2017)

Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial
by: Dafna Gladman, et al.
Published: (2023-10-01)

Measuring outcomes in psoriatic arthritis
by: Ogdie, A, et al.
Published: (2020)

Classification and outcome measures for psoriatic arthritis
by: Leung, Y, et al.
Published: (2018)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
by: Bernard Combe, et al.
Published: (2022-10-01)

Considerations for the definition of remission criteria in psoriatic arthritis
by: Mease, P, et al.
Published: (2017)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
by: Ogdie, A, et al.
Published: (2023)

Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid
by: Taylor, P, et al.
Published: (2018)

Current concepts and unmet needs in psoriatic arthritis
by: Mahmood, F, et al.
Published: (2017)

Filgotinib for the treatment of rheumatoid arthritis
by: Taylor, P, et al.
Published: (2017)

Filgotinib, a Janus kinase 1 (JAK1)-selective inhibitor, modulates disease associated cytokines in patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019)

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study
by: Nash, P, et al.
Published: (2018)

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
by: Nash, P, et al.
Published: (2018)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
by: Coates, L, et al.
Published: (2019)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
by: Gladman, DD, et al.
Published: (2018)

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
by: Helliwell, P, et al.
Published: (2018)

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
by: Tillett, W, et al.
Published: (2017)

Best-practice indicators in Psoriatic disease care
by: Helliwell, P, et al.
Published: (2019)

Assessing disease activity in psoriatic arthritis: a literature review
by: Tucker, L, et al.
Published: (2018)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
by: Alexis Ogdie, et al.
Published: (2023-05-01)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
by: Mease, P, et al.
Published: (2018)

Selective inhibition of Janus kinase 1 (JAK1) by filgotinib modulates the disease-associated whole blood transcriptional profile of patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
by: Helliwell, PS, et al.
Published: (2022)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
by: Mease, PJ, et al.
Published: (2019)

Janus kinase inhibitors in the treatment of psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2022-02-01)

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation
by: Coates, L, et al.
Published: (2016)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
by: Coates, L, et al.
Published: (2020)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
by: Mease, P, et al.
Published: (2017)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
by: Coates, L, et al.
Published: (2016)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
by: Coates, L, et al.
Published: (2017)

Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership: Recommended next steps
by: Tillett, W, et al.
Published: (2020)

Methotrexate in psoriasis and psoriatic arthritis
by: Coates, L, et al.
Published: (2020)

Sustained very low disease activity and remission in psoriatic arthritis patients
by: Lubrano, E, et al.
Published: (2019)

Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis
by: Leung, YY, et al.
Published: (2020)

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
by: Toshifumi Hibi, et al.
Published: (2023-01-01)

Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-severely Active Rheumatoid Arthritis (FINCH3)
by: Taylor, P, et al.
Published: (2020)

Psoriatic arthritis
by: FitzGerald, O, et al.
Published: (2021)

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
by: Alejandro Balsa, et al.
Published: (2023-09-01)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
by: Coates, L, et al.
Published: (2022)